Three-minute bladder-cancer test launched in US:
This article was originally published in Clinica
Executive Summary
CR Bard's three-minute bladder-cancer test, the Bard BTA, was launched in the US at the 1st International Bladder Symposium at the end of last week. The test, developed by Seattle-based Bard Diagnostic Sciences, received US FDA approval late last year and has been on sale in Europe for one year (see Clinica No 683, p 20).